Changes
/* Factors Affecting Rx-to-OTC Switch */
====Market Overview====
[[Image:Market Overview.jpg|center|thumb|800px]]
====Sales Data for Selected Rx-to-OTC Switches, USA====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#CCCCFF"|'''S.No'''
|align = "center" bgcolor = "#CCCCFF"'''Switched Drug'''
|align = "center" bgcolor = "#CCCCFF"'''Manufacturer/Marketer'''
|align = "center" bgcolor = "#CCCCFF"'''Drug Category'''
|align = "center" bgcolor = "#CCCCFF"'''Switch Year'''
|align = "center" bgcolor = "#CCCCFF"'''First 12-Month Sales (in millions)'''
|-
|align = "center"|1
|Aleve
|Bayer Consumer Care
|Analgesic
|1994
|align = "center"|$110
|-
|align = "center"|2
|Alli
|GlaxoSmithKline Consumer Healthcare
|Weight Loss Aid
|2007
|align = "center"|$80
|-
|align = "center"|3
|Claritin
|Schering-Plough Healthcare
|Allergy
|2002
|align = "center"|$380
|-
|align = "center"|4
|MiraLax
| Schering-Plough Healthcare
|Gastrointestinal
|2006
|align = "center"|$40
|-
|align = "center"|5
|Nicoderm CQ
|GlaxoSmithKline Consumer Healthcare
|Smoking Cessation
|1996
|align = "center"|$160
|-
|align = "center"|6
|Nicorette
|GlaxoSmithKline Consumer Healthcare
|Smoking Cessation
|1996
|align = "center"|$195
|-
|align = "center"|7
|Pepcid AC
|Johnson & Johnson - Merck Consumer Pharmaceuticals Co.
|Gastrointestinal
|1995
|align = "center"|$200
|-
|align = "center"|8
|Prilosec OTC
|Procter & Gamble
|Gastrointestinal
|2003
|align = "center"|$130
|-
|align = "center"|9
|Rogaine
|McNeil Consumer Healthcare
|Hair Loss
|1996
|align = "center"|$180
|-
|align = "center"|10
|Zantac 75
|Boehringer Ingelheim Consumer Healthcare Products
|Gastrointestinal
|1995
|align = "center"|$140
|-
|}<br><br>
====Factors Affecting Rx-to-OTC Switch====
'''Consumers:''' In the current scenario, consumers are looking to cut their health care costs<br>
